Suggested remit: To appraise the clinical and cost effectiveness of bimekizuamb within its marketing authorisation for treating moderate to severe plaque psoriasis.
Status In progress
Process STA 2018
ID number 2692

Provisional Schedule

Committee meeting: 1 07 July 2021
Expected publication 22 September 2021

Project Team

Project lead Shonagh D'Sylva

Email enquiries

Evidence Review Group / Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton


Companies sponsors UCB Pharma (bimekizumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Psoriasis Association
  Psoriasis and Psoriatic Arthritis Alliance
Professional groups British Association of Dermatologists
  Royal College of Physicians


Comparator companies AbbVie Ltd (adalimumab, risankizumab)
  Almirall Limited (dimethyl fumarate, tildrakizumab)
  Amgen Ltd (adalimumab, apremilast)
  Biogen Biosimilars (adalimumab, etanercept, infliximab) (not participating)
  Biogen Idec Ltd (dimethyl fumarate) (not participating)
  Celltrion Healthcare UK Limited (infliximab) (not participating)
  Eli Lilly and Company Limited (ixekizumab)
  Janssen-Cilag Ltd (guselkumab, ustekinumab)
  Leo Laboratories Limited (brodalumab)
  MSD Limited (infliximab) (not participating)
  Mylan (adalimumab) (not participating)
  Napp Pharmaceuticals Limited (infliximab) (not participating)
  Novartis (secukinumab)
  Pfizer Limited (etanercept, infliximab)
  Sandoz limited (adalimumab, etanercept, infliximab) (not participating)
  UCB Pharma Limited (certolizumab pegol)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
27 October 2020 Invitation to participate
02 October 2020 In progress. Appraisal referred to NICE
21 July 2020 - 18 August 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance